Literature DB >> 24984178

The effect of a single nucleotide polymorphism of the CYP4F2 gene on blood pressure and 20-hydroxyeicosatetraenoic acid excretion after weight loss.

Natalie C Ward1, Kevin D Croft, Ian B Puddey, Michael Phillips, Frank van Bockxmeer, Lawrence J Beilin, Anne E Barden.   

Abstract

BACKGROUND: Genetic background partly determines the efficacy of interventions to lower blood pressure (BP). The CYP4F2 and CYP4A11 enzymes are renal 20-hydroxyeicosatetraenoic acid (20-HETE) synthases that regulate BP. Gene variants of CYP4F2 and CYP4A11 associate with hypertension and stroke. We showed that a gene variant of CYP4F2 but not CYP4A11 was associated with increased 20-HETE excretion and BP. AIM: To compare BP and 20-HETE responses in carriers of the CYP4F2 1347G/A polymorphism and controls CYP4F2-GG (wildtype), during weight loss.
METHODS: Volunteers genotyped as CYP4F2GA/AA (n = 26) and controls genotyped as CYP4F2 GG (n = 27) were counselled to reduce weight for 12 weeks, followed by 4 weeks of weight stabilization. Weight, 24-h BP, pulse pressure and urinary 20-HETE were measured at baseline, 12 and 16 weeks.
RESULTS: At baseline, SBP was (+1.7 mmHg, P = 0.047) in the CYP4F2 GA/AA genotype. Compared with baseline, weight fell by 3.9 kg, P = 0.0001, in both genotypes, and was maintained to 16 weeks. SBP fell by (-7.6 mmHg, P = 0.004) in both genotypes after 12 weeks. However, after weight stabilization, SBP was +3.6 mmHg, P = 0.004 in CYP4F2 GA/AA genotype. DBP and heart rate changed similarly over time. Pulse pressure fell with weight loss (P < 0.001), but was elevated in the CYP4F2 GA/AA genotype at all time-points (+3.1 mmHg, P < 0.001). Urinary 20-HETE was similar at baseline and 12 weeks but elevated in the CYP4F2 GA/AA genotype (P = 0.017) after weight stabilization.
CONCLUSION: Maintenance of lower BP after weight loss is more difficult for carriers of the CYP4F2 G1347A polymorphism and may be related to increased arterial stiffness and increased 20-HETE synthesis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24984178     DOI: 10.1097/HJH.0000000000000208

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  6 in total

1.  Correlation between CYP4F2 gene rs2108622 polymorphism and susceptibility to ischemic stroke.

Authors:  Chong Meng; Juan Wang; Wei-Ning Ge; Shao-Can Tang; Guang-Ming Xu
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 2.  PharmGKB summary: very important pharmacogene information for CYP4F2.

Authors:  Maria L Alvarellos; Katrin Sangkuhl; Roxana Daneshjou; Michelle Whirl-Carrillo; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2015-01       Impact factor: 2.089

Review 3.  Molecular mechanisms and cell signaling of 20-hydroxyeicosatetraenoic acid in vascular pathophysiology.

Authors:  Fan Fan; Ying Ge; Wenshan Lv; Matthew R Elliott; Yoshikazu Muroya; Takashi Hirata; George W Booz; Richard J Roman
Journal:  Front Biosci (Landmark Ed)       Date:  2016-06-01

4.  High-fat diet-induced obesity and insulin resistance in CYP4a14-/- mice is mediated by 20-HETE.

Authors:  Ankit Gilani; Varunkumar Pandey; Victor Garcia; Kevin Agostinucci; Shailendra P Singh; Joseph Schragenheim; Lars Bellner; John R Falck; Mahesh P Paudyal; Jorge H Capdevila; Nader G Abraham; Michal Laniado Schwartzman
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2018-08-08       Impact factor: 3.619

Review 5.  Cytochrome P450 eicosanoids in hypertension and renal disease.

Authors:  Fan Fan; Yoshikazu Muroya; Richard J Roman
Journal:  Curr Opin Nephrol Hypertens       Date:  2015-01       Impact factor: 2.894

6.  Genetic variants in CYP4F2 were significantly correlated with susceptibility to ischemic stroke.

Authors:  Yuan Wu; Junjie Zhao; Yonglin Zhao; Tingqin Huang; Xudong Ma; Honggang Pang; Ming Zhang
Journal:  BMC Med Genet       Date:  2019-09-11       Impact factor: 2.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.